This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Jubilant Episcribe LLC. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: **Innovative Contributions of Sayantani Sarkar in Pharmaceutical Research**
Introduction
Sayantani Sarkar, located in Bengaluru, India, is a distinguished inventor known for her significant contribution to the field of pharmaceutical research. With one patent to her name, her innovative work focuses on the development of heterocyclic compounds with the potential to inhibit PRMT5, a target of interest in various pathological conditions.
Latest Patents
Sayantani’s notable patent, titled **Heterocyclic Compounds as PRMT5 Inhibitors**, encompasses a range of compounds, including those represented by Formula I, Formula Ia, and Formula Ib. The patent details their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs. These compounds are particularly promising as therapeutic agents for treating diseases related to cellular growth, including malignant tumors, schizophrenia, Alzheimer’s disease, and Parkinson's disease.
Career Highlights
Sayantani Sarkar is currently employed at Jubilant Episcribe LLC, where her research and development efforts are focused on creating novel pharmaceutical solutions. Her expertise in pharmacology and drug design has positioned her as a key player in her organization, contributing to advancements in therapeutic strategies.
Collaborations
In her professional journey, Sayantani has been privileged to collaborate with esteemed colleagues, including Saravanan Vadivelu and Sridharan Rajagopal. These collaborations underscore the importance of teamwork in driving innovative research forward and achieving shared goals in drug discovery.
Conclusion
Sayantani Sarkar’s innovative work is a testament to her dedication and expertise in pharmaceutical research. Her patent on PRMT5 inhibitors not only showcases her inventive spirit but also highlights her role in addressing significant health challenges. As she continues her work at Jubilant Episcribe LLC, she remains a pivotal figure in the realm of drug development, with the potential to impact the lives of many through her contributions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile